$NKE

Nike is taking on water from (almost) all sides

Nike reported a 4% revenue decline in Q1 2027, with management forecasting a 'high single-digit' decrease for the full fiscal year. Sales fell in China, Europe, and other regions, while the direct-sales strategy underperformed. Converse sales halved. Cost cuts helped maintain margins, with EPS at $0.48 and a slight dividend increase. Share buybacks have halted.

Original reporting
Published Oct 2, 2026, 8:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NKE
Bearish
high confidence
Mentioned
$NKE
Relevance
9/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$NKEBearishHigh
01

Why it matters

The earnings miss and lowered outlook are likely to drive the stock lower in early trading.

02

Market read

Nike’s earnings are a primary catalyst for the sportswear sector and broader consumer discretionary market.

03

What to watch

Cost‑cutting and margin expansion could cushion earnings despite revenue decline.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Nike released its Q1 2027 earnings, the first public disclosure of the quarter's results and guidance.

Company-level read

Ticker impact

$NKEBearishHigh confidence
Context

Nike Q1 2027 results show a 4% revenue decline and guidance of a high single‑digit decrease, with $332M revenue loss in China and $372M overall, indicating weaker performance.

Expected impact

downward pressure as investors price in weaker revenue and guidance

Evidence & confidence

The first‑report earnings release contains material revenue decline and guidance cuts for a large cap, which historically moves the stock lower.

Market effects

Sportswear sector faces pressure as Nike's slowdown may prompt re‑rating of peers.

China and Europe markets could see broader retail weakness.

Nike's size makes the earnings miss a global market mover.

Counterpoint

If Nike can quickly turn around China sales, the dip may be over‑stated.

Key entities

  • Nike

    World’s leading sportswear manufacturer, ticker NKE.

Related articles

$NKEHigh

Jefferies cuts Nike stock price target on China, Jordan headwinds

Jefferies reduced its price target for Nike (NYSE: NKE) to $60 from $75, citing challenges in China and the Jordan brand. Nike's stock is down 51% over the past year. The company reported Q1 earnings beating estimates but missing revenue expectations, with a 26% decline in Greater China revenue. Nike projects a high-single-digit revenue decline for the fiscal year.

$NKEMed

NKE Stock Heads For A Weekly Loss: Morningstar Says Nike's Fresh Cost Cuts Signal A Longer Road To Recovery

Nike (NKE) stock is down 1.6% this week, with a 8% drop in premarket trading. Morningstar warns of a longer recovery due to weak Q1 sales, lower fiscal 2027 guidance, and China challenges. Nike plans $2.5B in savings via 'Pace' initiative, targeting tech and supply chain. Earnings per share estimate lowered to $1.15-$1.35. Retail sentiment remains bullish despite a 44% YTD decline.

$NKEHighAI 9/10

Why is Nike stock tumbling today?

Nike (NKE) stock dropped 9.6% after reporting mixed Q1 2027 results: earnings beat estimates ($0.48 vs. $0.44) but revenue missed ($11.21B vs. $11.35B). Full-year guidance was significantly lower than expected, with revenue projected to fall in the high single digits and EPS between $1.15 and $1.35. China sales declined 26%, and the company announced a restructuring plan targeting $2.5B in savings by 2031.

$NKEMed

Nike, Synaptics And 3 Stocks To Watch Heading Into Friday

Nike (NKE) reported mixed Q1 results, missing revenue estimates but beating earnings. Synaptics (SYNA) agreed to be acquired by ON Semiconductor (ON) for $123 per share. Edwards Lifesciences (EW) received FDA approval for a pediatric valve. AsiaStrategy (SORA) and Mangoceuticals (MGRX) made announcements, causing after-hours price swings.